Abstract: Osimertinib (AZD9291) is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). While it demonstrates remarkable efficacy against both sensitizing mutations and the T790M resistance mutation, acquired resistance inevitably limits its long-term utility. This review explores the pharmacological activity, molecular mechanisms, and structure-activity relationships of osimertinib. Furthermore, it highlights current limitations driven by on-target and off-target resistance mechanisms, such as the C797S mutation, MET amplification, and bypass signaling activation. Finally, it provides future perspectives focusing on combination therapeutics—including targeted agents, chemotherapy, immunotherapy, and repurposed drugs—as critical strategies to overcome resistance and prolong patient survival.
1. Introduction
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide, with activating mutations in the epidermal growth factor receptor (EGFR) gene serving as a major actionable therapeutic target [4][5]. The advent of first- and second-generation EGFR-TKIs (such as gefitinib, erlotinib, and afatinib) revolutionized the treatment paradigm for EGFR-mutated NSCLC. However, the clinical benefit of these early-generation TKIs is invariably curtailed by the emergence of acquired resistance, most commonly mediated by the EGFR T790M gatekeeper mutation [2][7]. Osimertinib (AZD9291) was rationally designed as a third-generation TKI to specifically overcome T790M-mediated resistance while sparing wild-type EGFR [2][8]. Despite its success and establishment as a standard-of-care first-line therapy, patients eventually develop resistance to osimertinib, typically within one to two years [1][3]. Consequently, the research focus has shifted toward combination therapeutics to delay the onset of resistance or to treat progressive disease, utilizing rational combinations with other targeted agents, chemotherapy, or repurposed drugs [1][5][6].
2. Pharmacological Activity
Osimertinib has demonstrated superior clinical efficacy compared to earlier generation TKIs. In the phase III AURA3 trial, osimertinib showed a significantly higher objective response rate (ORR) of 71% and a prolonged median progression-free survival (PFS) of 10.1 months compared to platinum-pemetrexed chemotherapy in patients with T790M-positive NSCLC who had progressed on prior EGFR-TKI therapy [7][8]. Subsequently, the landmark FLAURA study established osimertinib as a first-line treatment for EGFR-mutant advanced NSCLC, demonstrating a significantly improved median PFS (18.9 vs. 10.2 months) and overall survival (OS) (38.6 vs. 31.8 months) over standard TKIs (gefitinib or erlotinib) [7][11]. Furthermore, osimertinib exhibits excellent central nervous system (CNS) penetration, providing significant clinical activity against brain and leptomeningeal metastases, which is a common site of progression in NSCLC [2][5][7].
3. Molecular Mechanism of Action
Osimertinib is an irreversible TKI that covalently binds to the ATP-binding site of the EGFR kinase domain [2][8]. It specifically targets the cysteine-797 (C797) residue, thereby blocking aberrant signaling pathways essential for tumor cell survival and proliferation [1][2]. Preclinical data indicate that osimertinib has approximately 200 times greater potency against the L858R/T790M mutant than against wild-type EGFR [2]. This high selectivity for mutant EGFR over the wild-type receptor accounts for its reduced epithelial toxicity, resulting in lower incidences of severe skin rash and diarrhea compared to first- and second-generation TKIs [7][8].
4. Structure-Activity Relationship (SAR)
Structurally, osimertinib is a mono-anilino-pyrimidine compound, distinguishing it from the quinazoline-based first- and second-generation TKIs [2]. This unique structural scaffold allows it to selectively accommodate the bulky methionine side chain of the T790M mutated kinase while maintaining the ability to form a covalent bond with the Cys797 residue [2][8]. Pharmacokinetic studies have identified two circulating active metabolites of osimertinib, AZ5104 and AZ7550, both of which exhibit comparable potency to the parent compound against sensitizing EGFR mutations and the T790M mutation [2].
5. Current Limitations
The primary limitation of osimertinib is the inevitable development of acquired resistance, which occurs via complex EGFR-dependent (on-target) and EGFR-independent (off-target) mechanisms [5].
On-target resistance: The most common tertiary mutation is C797S, which alters the cysteine residue to serine, preventing the covalent binding of osimertinib to the EGFR kinase domain [5][8]. Other reported on-target mechanisms include uncommon mutations (e.g., L718Q) and amplification of wild-type EGFR alleles [1][3].
Off-target resistance: MET amplification is the most predominant bypass mechanism, occurring in 15-24% of cases [5][6][9]. Other bypass pathways include HER2 amplification, activation of the RAS/RAF/MEK/ERK pathway (e.g., KRAS, NRAS, and BRAF mutations), PI3K/AKT pathway alterations, and activation of alternative receptor tyrosine kinases such as AXL or IGF-1R [3][5][6]. Oncogenic fusions involving ALK, RET, and BRAF have also been identified [4][5].
Phenotypic changes: Epithelial-mesenchymal transition (EMT) and histological transformation to small-cell lung cancer (SCLC) or squamous cell carcinoma represent significant resistance mechanisms that render the tumor independent of EGFR signaling [3][4][6].
6. Future Perspectives
To overcome these limitations, combination therapeutics are being extensively investigated in preclinical and clinical settings:
MET Inhibitors: Combining osimertinib with MET inhibitors (e.g., savolitinib, crizotinib, capmatinib, tepotinib) has shown highly promising results in MET-amplified resistant tumors. The TATTON and SAVANNAH trials demonstrated encouraging anti-tumor activity and acceptable safety profiles for the combination of osimertinib and savolitinib [5][6][9][10][12].
MEK/ERK and Cell Cycle Inhibitors: Dual inhibition of EGFR and MEK (e.g., with selumetinib or trametinib) is being explored to counteract RAS/MAPK pathway activation [5][6]. Additionally, CDK4/6 inhibitors (e.g., palbociclib, abemaciclib) combined with osimertinib have shown potential in overcoming cell cycle-mediated resistance in preclinical models [3][5].
Antibodies and ADCs: The bispecific antibody amivantamab (targeting EGFR and MET) combined with lazertinib is under investigation in the CHRYSALIS study [6]. Combinations with cetuximab or antibody-drug conjugates (ADCs) like trastuzumab emtansine (targeting HER2) are also being evaluated to tackle bypass signaling [5][6][8].
Chemotherapy and Anti-angiogenics: The FLAURA2 and COMPEL trials are assessing the efficacy of combining osimertinib with platinum-based chemotherapy to delay resistance or treat progression [5][11][12]. Combinations with anti-angiogenic agents like bevacizumab or ramucirumab are also under clinical evaluation (e.g., WJOG9717L and RELAY trials) [5][10][11].
Repurposed Drugs: Novel approaches like the OPALS regimen (pyrimethamine, cyproheptadine, azithromycin, loratadine, spironolactone) aim to intersect with multiple growth pathways to delay resistance to osimertinib using inexpensive, generically available drugs [1].
